Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Sangamo Therapeutics, Inc. (SGMO : NSDQ)
 
 • Company Description   
Sangamo Therapeutics, Inc. is a biotechnology company. It focuses on research and development of genomic therapies as well as develops medicines for patient with genetic diseases. The Company's product pipeline includes SB-525, SB-FIX, SB-318, SB-913, SB-728-T and SB-728-HSPC. Sangamo Therapeutics Inc., formerly known as Sangamo BioSciences Inc., is based in Richmond, United States.

Number of Employees: 183

 
 • Price / Volume Information   
Yesterday's Closing Price: $0.50 Daily Weekly Monthly
20 Day Moving Average: 4,962,003 shares
Shares Outstanding: 233.17 (millions)
Market Capitalization: $116.58 (millions)
Beta: 1.23
52 Week High: $3.18
52 Week Low: $0.37
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -0.60% -4.32%
12 Week -29.14% -40.40%
Year To Date -50.98% -54.09%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
501 Canal Blvd
-
Richmond,CA 94804
USA
ph: 510-970-6000
fax: 510-236-8951
ir@sangamo.com http://www.sangamo.com
 
 • General Corporate Information   
Officers
Alexander D. Macrae - President; Chief Executive Officer
H. Stewart Parker - Director and Chair of the Board
Prathyusha Duraibabu - Senior Vice President and Chief Financial Officer
Courtney Beers - Director
Robert F. Carey - Director

Peer Information
Sangamo Therapeutics, Inc. (CORR.)
Sangamo Therapeutics, Inc. (RSPI)
Sangamo Therapeutics, Inc. (CGXP)
Sangamo Therapeutics, Inc. (BGEN)
Sangamo Therapeutics, Inc. (GTBP)
Sangamo Therapeutics, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 800677106
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/05/25
Share - Related Items
Shares Outstanding: 233.17
Most Recent Split Date: 6.00 (1.25:1)
Beta: 1.23
Market Capitalization: $116.58 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.09 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.38 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/05/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 23.36
Price/Cash Flow: -
Price / Sales: 1.83
EPS Growth
vs. Year Ago Period: 48.15%
vs. Previous Quarter: -27.27%
Sales Growth
vs. Year Ago Period: 1,238.25%
vs. Previous Quarter: -14.75%
ROE
06/30/25 - -
03/31/25 - -345.98
12/31/24 - -272.03
ROA
06/30/25 - -
03/31/25 - -79.86
12/31/24 - -89.01
Current Ratio
06/30/25 - -
03/31/25 - 0.76
12/31/24 - 1.13
Quick Ratio
06/30/25 - -
03/31/25 - 0.76
12/31/24 - 1.13
Operating Margin
06/30/25 - -
03/31/25 - -122.78
12/31/24 - -167.42
Net Margin
06/30/25 - -
03/31/25 - -124.61
12/31/24 - -169.45
Pre-Tax Margin
06/30/25 - -
03/31/25 - -124.84
12/31/24 - -169.74
Book Value
06/30/25 - -
03/31/25 - 0.02
12/31/24 - 0.11
Inventory Turnover
06/30/25 - -
03/31/25 - -
12/31/24 - -
Debt-to-Equity
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
Debt-to-Capital
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
 

Powered by Zacks Investment Research ©